RCM
TAK icon

Riverhead Capital Management’s Takeda Pharmaceutical TAK Stock Holding History

Riverhead Capital Management’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-12,741
Closed -$225K – 1537
2019
Q2 		$225K Buy
+12,741
New +$232K 0.01% 1102

Other funds holding TAK

GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
AC
Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Riverhead Capital Management's TAK Position: Q3 2019 in Review

Riverhead Capital Management sold out of Takeda Pharmaceutical (TAK) in Q3 2019, closing a stake of 12,741 shares — an estimated $225K sold.

Riverhead Capital Management first reported a position in TAK in Q2 2019 and held it in 1 quarter. The position peaked at $225K in Q2 2019. 317 funds tracked by Wall St. Rank hold TAK as of Q3 2019.

  • Riverhead Capital Management reported no remaining Takeda Pharmaceutical position as of Q3 2019 after selling out during the quarter.
  • Riverhead Capital Management sold 12,741 Takeda Pharmaceutical shares in Q3 2019, an estimated $225K.
  • Riverhead Capital Management first reported a position in Takeda Pharmaceutical in Q2 2019 and held it in 1 quarter.
  • Riverhead Capital Management's Takeda Pharmaceutical position peaked at $225K in Q2 2019.
  • 317 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.